SELB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 Nov 2023 @ 16:00):

Stats
Today's Volume	2.76M
Average Volume	634 418
Market Cap	135.20M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.04
ATR14	$0.0960 (14.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Singer Michael	Buy	178 000	Common Stock
2024-01-02	Singer Michael	Buy	228 000	Stock Option (Right to Buy)
2023-12-22	Singer Michael	Sell	3 000	Series A Convertible Preferred Stock
2024-01-02	Davis Blaine	Buy	3 110 000	Employee Stock Option (right to buy)
2024-01-02	Davis Blaine	Buy	2 424 000	Common Stock

INSIDER POWER
52.93
Last 97 transactions
Buy: 26 530 299 \| Sell: 8 848 103

Volume Correlation

Long: -0.24 (neutral)

Short: -0.32 (neutral)

Signal:(37.339) Neutral

Selecta Biosciences Inc Correlation

10 Most Positive Correlations
TCON	0.869
NLTX	0.855
MOGO	0.853
MAT	0.85
WHLM	0.847
SIFY	0.846
SKYX	0.839
KZIA	0.839
LTRPA	0.834
OTLY	0.834

10 Most Negative Correlations
AMRB	-0.834
RAVN	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Selecta Biosciences Inc Correlation - Currency/Commodity

0.12
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.16
( neutral )

-0.15
( neutral )

-0.20
( neutral )

Selecta Biosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00140

Q3	2023
Revenue:	$6.55M
Gross Profit:	$6.55M (100.00 %)
EPS:	$-0.0582

Q2	2023
Revenue:	$5.25M
Gross Profit:	$-12.53M (-238.77 %)
EPS:	$-0.0742

Q1	2023
Revenue:	$5.94M
Gross Profit:	$-12.69M (-213.64 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Selecta Biosciences Inc

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.